RT @SABOURETCardio: Evolocumab in HIV-Infected Patients With Dyslipidemia | JACC. Congratulations to @BoccaraFranck #cardiotwitter #lipid…
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/gMDqU6yT6L
RT @TLeucker: More evidence of the benefit of PCSK9 inhibition in HIV https://t.co/JNiJuXq9z3 @BoccaraFranck
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
More evidence of the benefit of PCSK9 inhibition in HIV https://t.co/JNiJuXq9z3 @BoccaraFranck
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/gMDqU6yT6L
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/gMDqU6QtYj
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/gMDqU6yT6L
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
New2Trip: Evolocumab in HIV-Infected Patients w/ Dyslipidemia: Primary Results of Randomized, Double-Blind BEIJERINCK Study https://t.co/ZZdTNSohnv
RT @SABOURETCardio: Evolocumab in HIV-Infected Patients With Dyslipidemia | JACC. Congratulations to @BoccaraFranck #cardiotwitter #lipid…
RT @JACCJournals: For people living with #HIV, new #JACC study suggests evolocumab is safe and effective in lowering lipids: https://t.co/y…
Evolocumab in HIV-Infected Patients With Dyslipidemia https://t.co/KdlMA3EODp
RT @JACCJournals: For people living with #HIV, new #JACC study suggests evolocumab is safe and effective in lowering lipids: https://t.co/y…
RT @JACCJournals: For people living with #HIV, new #JACC study suggests evolocumab is safe and effective in lowering lipids: https://t.co/y…
RT @JACCJournals: For people living with #HIV, new #JACC study suggests evolocumab is safe and effective in lowering lipids: https://t.co/y…
RT @JACCJournals: For people living with #HIV, new #JACC study suggests evolocumab is safe and effective in lowering lipids: https://t.co/y…
RT @JACCJournals: For people living with #HIV, new #JACC study suggests evolocumab is safe and effective in lowering lipids: https://t.co/y…
For people living with #HIV, new #JACC study suggests evolocumab is safe and effective in lowering lipids: https://t.co/yJrKPWee0g @BoccaraFranck https://t.co/uwCMZKyAAO
RT @SABOURETCardio: Evolocumab in HIV-Infected Patients With Dyslipidemia | JACC. Congratulations to @BoccaraFranck #cardiotwitter #lipid…
RT @SABOURETCardio: Evolocumab in HIV-Infected Patients With Dyslipidemia | JACC. Congratulations to @BoccaraFranck #cardiotwitter #lipid…
RT @pnatarajanmd: In RCT of 464 people living with HIV also with hyperlipidemia on max tolerated statin, evolocumab 420mg sq q4w decreased…
In RCT of 464 people living with HIV also with hyperlipidemia on max tolerated statin, evolocumab 420mg sq q4w decreased LDL-C by 57% vs placebo. No significant difference in adverse event rates https://t.co/hUZsdCdXCt @JACCJournals #cvPrev https://t.co/l4
Evolocumab in HIV-Infected Patients With Dyslipidemia | JACC. Congratulations to @BoccaraFranck #cardiotwitter #lipids #PCSK9 I https://t.co/31gVz6qcsM
Important and interesting work by @BoccaraFranck et al. on safety and efficacy of evolocumab in HIV patients ! https://t.co/WtMVX1QpDk
Evolocumab in HIV-Infected Patients With Dyslipidemia | JACC: Journal of the American College of Cardiology https://t.co/SbXm8Jbuf1
RT @DaveDixonPharmD: Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK…
RT @DaveDixonPharmD: Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK…
RT @DaveDixonPharmD: Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK…
Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK Study https://t.co/ZTVpzvI7yo
RT @JACCJournals: People with #HIV are at increased risk of #ASCVD & statin-related adverse events. The BEIJERINCK study examines the #PCSK…
RT @JACCJournals: People with #HIV are at increased risk of #ASCVD & statin-related adverse events. The BEIJERINCK study examines the #PCSK…
Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK Study https://t.co/PnxZ1TDSY3 https://t.co/xgas3IfLy3
RT @JACCJournals: People with #HIV are at increased risk of #ASCVD & statin-related adverse events. The BEIJERINCK study examines the #PCSK…
RT @JACCJournals: People with #HIV are at increased risk of #ASCVD & statin-related adverse events. The BEIJERINCK study examines the #PCSK…
RT @JACCJournals: People with #HIV are at increased risk of #ASCVD & statin-related adverse events. The BEIJERINCK study examines the #PCSK…